AbbVie (ABBV) Non-Current Debt (2012 - 2026)

AbbVie has disclosed Non-Current Debt across 15 years of filings, most recently posting $64.5 billion for Q1 2026.

• In Q1 2026, Non-Current Debt changed 0.01% year-over-year to $64.5 billion; the TTM figure through Mar 2026 stood at $64.5 billion (changed 0.01% YoY), while the FY2025 annual figure was $58.9 billion, down 2.32% from the prior year.
• Non-Current Debt rose to $64.5 billion in Q1 2026, from $58.9 billion in the prior quarter.
• Over the last five years, Non-Current Debt for ABBV reached as high as $64.5 billion in Q1 2026 and fell as low as $52.2 billion in Q4 2023.
• The 5-year median for Non-Current Debt is $60.3 billion (2024), against an average of $60.1 billion.
• Annual changes were most pronounced in 2022 — Non-Current Debt slipped 18.43% — and 2024, when it climbed 15.61%.
• A 5-year view of Non-Current Debt shows it stood at $59.1 billion in 2022, then declined by 11.74% to $52.2 billion in 2023, then gained by 15.61% to $60.3 billion in 2024, then slipped by 2.32% to $58.9 billion in 2025, then rose by 9.49% to $64.5 billion in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $64.5 billion, $58.9 billion, and $63.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.